Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)
Other Treatments Global Adoption
Outcomes in COVID-19 convalescent plasma studies
Home   
Share  
Tweet
  StudiesStudies
  Global AdoptionAdoption
  Submit FeedbackFeedback
All studies   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -1% 14 15,607 Improvement, Studies, Patients Relative Risk Mortality -1% 14 15,607 Ventilation -1% 5 738 ICU admission 49% 2 1,341 Hospitalization 25% 4 1,761 Progression 11% 5 1,274 Recovery -1% 2 11,644 Viral clearance 41% 3 420 RCTs -1% 14 15,607 RCT mortality -1% 14 15,607 Peer-reviewed -0% 13 15,578 Early -93% 3 716 Late -0% 11 14,891 Convalescent Plasma for COVID-19 c19early.com/cp May 2022 Favorsconv. plasma Favorscontrol
0 0.5 1 1.5+ ALL STUDIES MORTALITY VENTILATION ICU ADMISSION HOSPITALIZATION PROGRESSION RECOVERY VIRAL CLEARANCE RCTS RCT MORTALITY PEER-REVIEWED All Early Late Convalescent Plasma for COVID-19 C19EARLY.COM/CP MAY 2022
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Late treatment -0% 1.00 [0.94-1.06] 1,642/7,681 1,567/7,210 -0% improvement All studies -1% 1.01 [0.88-1.15] 1,654/8,039 1,574/7,568 -1% improvement 14 convalescent plasma COVID-19 studies c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 10.6%, p = 0.92 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Late treatment -0% 1.00 [0.94-1.06] 1,642/7,681 1,567/7,210 -0% improvement All studies -1% 1.01 [0.88-1.15] 1,654/8,039 1,574/7,568 -1% improvement 14 convalescent plasma COVID-19 mortality results c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 10.6%, p = 0.92 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -163% 2.63 [0.43-9.10] 5/28 2/30 Tau​2​ = 0.70, I​2​ = 50.9%, p = 0.85 Early treatment -18% 1.18 [0.23-6.01] 7/108 6/110 -18% improvement Agarwal (RCT) 1% 0.99 [0.54-1.81] 19/227 19/224 Improvement, RR [CI] Treatment Control Bajpai (RCT) -221% 3.21 [0.38-27.4] 3/14 1/15 AlQahtani (RCT) 33% 0.67 [0.22-2.01] 4/20 6/20 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.92 Late treatment 3% 0.97 [0.58-1.63] 26/261 26/259 3% improvement All studies -1% 1.01 [0.63-1.62] 33/369 32/369 -1% improvement 5 convalescent plasma COVID-19 mechanical ventilation results c19early.com/cp May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 67% 0.33 [0.07-1.60] 2/80 6/80 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.17 Early treatment 67% 0.33 [0.07-1.60] 2/80 6/80 67% improvement Sullivan (DB RCT) 25% 0.75 [0.17-3.32] 3/592 4/589 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.71 Late treatment 25% 0.75 [0.17-3.32] 3/592 4/589 25% improvement All studies 49% 0.51 [0.17-1.49] 5/672 10/669 49% improvement 2 convalescent plasma COVID-19 ICU results c19early.com/cp May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.55 Early treatment 10% 0.90 [0.64-1.26] 51/257 56/254 10% improvement Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Improvement, RR [CI] Treatment Control AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 Tau​2​ = 0.02, I​2​ = 29.3%, p = 0.0064 Late treatment 30% 0.70 [0.54-0.90] 17/626 37/624 30% improvement All studies 25% 0.75 [0.61-0.93] 68/883 93/878 25% improvement 4 convalescent plasma COVID-19 hospitalization results c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 27.4%, p = 0.0083 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Late treatment -0% 1.00 [0.94-1.06] 1,642/7,681 1,567/7,210 -0% improvement All studies -1% 1.01 [0.88-1.15] 1,654/8,039 1,574/7,568 -1% improvement 14 convalescent plasma COVID-19 serious outcomes c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 10.6%, p = 0.92 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Improvement, RR [CI] Treatment Control Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.74 Late treatment -1% 1.01 [0.96-1.06] 1,963/5,838 1,941/5,806 -1% improvement All studies -1% 1.01 [0.96-1.06] 1,963/5,838 1,941/5,806 -1% improvement 2 convalescent plasma COVID-19 recovery results c19early.com/cp May 2022 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.74 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Improvement, RR [CI] Treatment Control Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) Tau​2​ = 0.09, I​2​ = 59.2%, p = 0.021 Late treatment 41% 0.59 [0.37-0.92] 60/213 91/207 41% improvement All studies 41% 0.59 [0.37-0.92] 60/213 91/207 41% improvement 3 convalescent plasma COVID-19 viral clearance results c19early.com/cp May 2022 Tau​2​ = 0.09, I​2​ = 59.2%, p = 0.021 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Late treatment -0% 1.00 [0.94-1.06] 1,642/7,681 1,567/7,210 -0% improvement All studies -1% 1.01 [0.88-1.15] 1,654/8,039 1,574/7,568 -1% improvement 14 convalescent plasma COVID-19 Randomized Controlled Trials c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 10.6%, p = 0.92 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.97 Late treatment -0% 1.00 [0.94-1.06] 1,642/7,681 1,567/7,210 -0% improvement All studies -1% 1.01 [0.88-1.15] 1,654/8,039 1,574/7,568 -1% improvement 14 convalescent plasma COVID-19 RCT mortality results c19early.com/cp May 2022 Tau​2​ = 0.01, I​2​ = 10.6%, p = 0.92 Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2​ = 0.74, I​2​ = 47.5%, p = 0.37 Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Tau​2​ = 0.00, I​2​ = 0.0%, p = 1. Late treatment -0% 1.00 [0.94-1.06] 1,639/7,667 1,566/7,195 -0% improvement All studies -0% 1.00 [0.90-1.12] 1,651/8,025 1,573/7,553 -0% improvement 13 convalescent plasma COVID-19 peer reviewed trials c19early.com/cp May 2022 Tau​2​ = 0.00, I​2​ = 6.3%, p = 0.95 Effect extraction pre-specified(most serious outcome) Favors conv. plasma Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Libster (DB RCT) 50% 0.50 [0.09-2.65] ventilation 2/80 4/80 Libster (DB RCT) 67% 0.33 [0.07-1.60] ICU 2/80 6/80 Libster (DB RCT) 48% 0.52 [0.29-0.94] progression 13/80 25/80 Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Balcells (RCT) -163% 2.63 [0.43-9.10] ventilation 5/28 2/30 Balcells (RCT) -23% 1.23 [0.56-1.89] progression 13/28 12/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Korley (RCT) 10% 0.90 [0.64-1.26] hosp. 51/257 56/254 Korley (RCT) 6% 0.94 [0.72-1.22] progression 77/257 81/254 Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Gharbharan (RCT) 12% 0.88 [0.49-1.60] no disch. 43 (n) 43 (n) Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Li (RCT) 15% 0.85 [0.53-1.18] no improv. 25/52 29/51 Li (RCT) 76% 0.24 [0.07-0.64] viral+ 4/26 15/23 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Avendaño-Solà (RCT) 93% 0.07 [0.00-1.19] progression 0/38 7/43 Avendaño-Solà (RCT) 92% 0.08 [0.00-1.40] progression 0/38 6/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Agarwal (RCT) -7% 1.07 [0.73-1.58] progression 44/235 41/229 Agarwal (RCT) 1% 0.99 [0.54-1.81] ventilation 19/227 19/224 Agarwal (RCT) 28% 0.72 [0.55-0.95] viral+ 56/173 76/169 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 Bajpai (RCT) -114% 2.14 [0.22-21.1] death 2/14 1/15 Bajpai (RCT) -221% 3.21 [0.38-27.4] ventilation 3/14 1/15 Bajpai (RCT) 25% 0.75 [0.55-1.04] hosp. time 14 (n) 15 (n) Bajpai (RCT) 32% 0.68 [0.42-1.09] viral load 14 (n) 15 (n) AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 AlQahtani (RCT) 33% 0.67 [0.22-2.01] ventilation 4/20 6/20 AlQahtani (RCT) 22% 0.78 [0.57-1.07] hosp. time 20 (n) 20 (n) Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Simonovich (RCT) 19% 0.81 [0.50-1.31] 7-point status 228 (n) 105 (n) Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Recovery Co.. (RCT) -1% 1.01 [0.97-1.06] no disch. 1,963/5,795 1,941/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Bégin (RCT) -12% 1.12 [0.86-1.46] death 141/614 63/307 Bégin (RCT) -16% 1.16 [0.94-1.43] death/int. 199/614 86/307 Sullivan (DB RCT) 86% 0.14 [0.01-2.75] death 0/592 3/589 Sullivan (DB RCT) 25% 0.75 [0.17-3.32] ICU 3/592 4/589 Sullivan (DB RCT) 54% 0.46 [0.26-0.80] hosp. 17/592 37/589 convalescent plasma COVID-19 outcomes c19early.com/cp May 2022 Favors conv. plasma Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0